Science
Biology, diagnostics and the systems reshaping human health.
THE NKENGBEZA LEDGER · INDEPENDENT RESEARCH
Discover the Catalyst.Test the Commercial Impact.Track the Outcome.
Evidence-led research on discoveries, launches and deals that could reshape earnings across science, technology and finance.
Technology
The infrastructure and software compounding human capability.
Finance
Institutions, assets and the architecture of capital.
Featured work
Research under development
Initiation projectWGS · NASDAQ
Can GeneDx turn its rare-disease data advantage into durable profitability?
A developing thesis on genomic diagnostics, AI-assisted interpretation and the economics of moving exome and genome sequencing earlier in pediatric care.
Research in progressUpdated August 5, 2026
Open research project →Q2 2026 snapshotCompany reported
Revenue$114.4M11% year over year
Exome + genome volume30,78532% year over year
Adjusted gross margin70%68% GAAP
2026 revenue guide$475–490M≥30% volume growth
Source: GeneDx Q2 2026 results. Figures are not forecasts or recommendations.
THE LEDGER STANDARD
Evidence before narrative.
Each thesis begins with a falsifiable question, separates reported facts from estimates, and identifies what would change the conclusion.
- 01Find the catalyst
- 02Model the impact
- 03Challenge the thesis
- 04Track the outcome